Source:http://linkedlifedata.com/resource/pubmed/id/21189262
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
13
|
| pubmed:dateCreated |
2011-4-1
|
| pubmed:abstractText |
Lenalidomide plays an important role in our chemotherapeutic armamentarium against multiple myeloma, in part by exerting direct anti-proliferative and pro-apoptotic effects. Unfortunately, long-term exposure leads to the development of drug resistance through unknown mechanisms, and we therefore sought to identify pathways that could be responsible for this phenotype. Chronic drug exposure produced myeloma cell lines that were tolerant of the direct effects of lenalidomide, with a degree of resistance of up to 2,500-fold. Gene expression profiling and pathway analysis identified dysregulation of the Wnt/?-catenin pathway as a consistent change across four independent cell isolates, and a pair of primary plasma cell samples. Acute drug treatment also increased ?-catenin transcription by 3-fold or more, and both acute and chronic exposure resulted in enhanced accumulation of ?-catenin protein by up to 20-fold or more. This produced Wnt/?-catenin pathway activation, as judged by increased activity of a lymphoid enhancer factor/T-cell factor promoter reporter, and enhanced accumulation of the downstream targets cyclin D1 and c-Myc. Components of the ?-catenin destruction complex were also impacted by lenalidomide, which suppressed casein kinase 1? expression while augmenting glycogen synthase kinase 3?/? phosphorylation. Stimulation of Wnt/?-catenin signaling with recombinant Wnt-3a, or by overexpression of ?-catenin, reduced the anti-proliferative activity of lenalidomide. Conversely, suppression of ?-catenin with small hairpin RNAs restored plasma cell sensitivity to lenalidomide. Together, these findings support the hypothesis that lenalidomide mediates activation of Wnt/?-catenin signaling in plasma cells as a mechanism of inducible chemoresistance through effects at the transcriptional and post-translational levels.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/CCND1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Casein Kinase Ialpha,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin D1,
http://linkedlifedata.com/resource/pubmed/chemical/Glycogen Synthase Kinase 3,
http://linkedlifedata.com/resource/pubmed/chemical/MYC protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-myc,
http://linkedlifedata.com/resource/pubmed/chemical/Thalidomide,
http://linkedlifedata.com/resource/pubmed/chemical/WNT3A protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Wnt Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Wnt3 Protein,
http://linkedlifedata.com/resource/pubmed/chemical/Wnt3A Protein,
http://linkedlifedata.com/resource/pubmed/chemical/beta Catenin,
http://linkedlifedata.com/resource/pubmed/chemical/glycogen synthase kinase 3 alpha,
http://linkedlifedata.com/resource/pubmed/chemical/glycogen synthase kinase 3 beta,
http://linkedlifedata.com/resource/pubmed/chemical/lenalidomide
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
1083-351X
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:day |
1
|
| pubmed:volume |
286
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
11009-20
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:21189262-Antineoplastic Agents,
pubmed-meshheading:21189262-Casein Kinase Ialpha,
pubmed-meshheading:21189262-Cell Line, Tumor,
pubmed-meshheading:21189262-Cyclin D1,
pubmed-meshheading:21189262-Drug Resistance, Neoplasm,
pubmed-meshheading:21189262-Gene Expression Regulation, Enzymologic,
pubmed-meshheading:21189262-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:21189262-Glycogen Synthase Kinase 3,
pubmed-meshheading:21189262-Humans,
pubmed-meshheading:21189262-Multiple Myeloma,
pubmed-meshheading:21189262-Plasma Cells,
pubmed-meshheading:21189262-Proto-Oncogene Proteins c-myc,
pubmed-meshheading:21189262-Signal Transduction,
pubmed-meshheading:21189262-Thalidomide,
pubmed-meshheading:21189262-Transcription, Genetic,
pubmed-meshheading:21189262-Wnt Proteins,
pubmed-meshheading:21189262-Wnt3 Protein,
pubmed-meshheading:21189262-Wnt3A Protein,
pubmed-meshheading:21189262-beta Catenin
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.
|
| pubmed:affiliation |
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|